The 65th Annual Meeting of the Japan Society of Clinical Oncology【Fukuoka Prefecture】
The 65th Annual Meeting of the Japan Society of Clinical Oncology (JSCO2027) is scheduled for October 14–16, 2027 (Thursday–Saturday), at Fukuoka Convention Center in Fukuoka, Japan. The meeting theme is “Passion and Collaboration” (English translation of 情熱と協調). The meeting president is Dr. Hideaki Miyake of the Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine. The meeting provides a multidisciplinary forum for scientific and clinical exchange in cancer diagnosis, surgery, systemic therapy, radiation therapy, cancer immunotherapy and personalized medicine. The society’s preliminary planning document anticipates approximately 8,000 participants, 1,800 abstract submissions and 45 corporate exhibitors, making the event relevant to pharmaceutical, diagnostic, research instrument, reagent and drug discovery service companies.
Meeting Theme and Objectives
Passion and Collaboration
Official Japanese theme: 情熱と協調. The English wording is a translation for this event listing.
The Japan Society of Clinical Oncology promotes scientific exchange across specialties involved in cancer treatment. Its activities support progress in understanding cancer, diagnosis, treatment development, clinical research, healthcare professional education, and support for patients and families.
The announced theme of the 65th annual meeting emphasizes passion and collaboration. Cooperation across clinical specialties, healthcare professions and scientific disciplines is an important perspective in translating research into cancer care. The meeting president’s message and detailed explanation of the theme should be confirmed in forthcoming official announcements.
Official information: 65th Annual Meeting Overview and Preliminary Planning Document (Japanese)
65th Annual Meeting of the Japan Society of Clinical Oncology: Event Information
- Official English Name: The 65th Annual Meeting of the Japan Society of Clinical Oncology (JSCO2027).
- Official Japanese Name: 第65回日本癌治療学会学術集会.
- Dates: October 14–16, 2027 (Thursday–Saturday).
- Venue: Fukuoka Convention Center.
- Location: Fukuoka, Japan.
- Organizer: Japan Society of Clinical Oncology (JSCO).
- Meeting Theme: Passion and Collaboration (English translation).
- Meeting Format: A physical venue has been announced. Online streaming and hybrid participation arrangements have not been confirmed.
- Dedicated Meeting Website: Under preparation; currently verified official information is available through the society’s meeting schedule and preliminary planning document.
Official information: JSCO Future Meetings (English) / Upcoming Annual Meetings (Japanese)
Meeting Organization
Meeting President: Dr. Hideaki Miyake, Professor, Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine.
Dr. Miyake specializes in urological oncology and minimally invasive urological surgery. Kobe University’s official faculty profile identifies him as professor and department head. His clinical field is relevant to treatment research in urological cancers, including renal, prostate and urothelial cancers.
- Society Secretariat: Japan Society of Clinical Oncology.
- Address: TKi Building 2F, 3-3-1 Kanda Misakicho, Chiyoda-ku, Tokyo 101-0061, Japan.
- Tel: +81-3-5542-0546.
- Fax: +81-3-5542-0547.
- Dedicated Meeting Secretariat and Meeting Management Contractor: Details not confirmed.
The above contact details are for the society’s general secretariat, not a dedicated office for the 65th annual meeting.
Official information: Kobe University Division of Urology Faculty Profile (Japanese) / JSCO Overview and Secretariat (Japanese)
Key Research Areas and Highlights
The following are representative research and clinical areas relevant to cancer treatment and JSCO scientific activities. They do not constitute a confirmed list of sessions at the 65th annual meeting.
- Systemic Cancer Therapy: Anticancer drugs, molecularly targeted therapies, therapeutic antibodies, antibody-drug conjugates (ADCs), combination therapies and drug resistance.
- Cancer Immunotherapy: Immune checkpoint inhibitors, antitumor immune responses, the tumor microenvironment and predictive biomarkers of treatment response.
- Cancer Genomics and Personalized Medicine: Gene panel testing, next-generation sequencing (NGS), molecular diagnostics and genomic information guiding treatment selection.
- Surgery and Radiation Therapy: Minimally invasive surgery, robot-assisted surgery, radiation therapy, multimodal treatment and perioperative management.
- Clinical Trials and Translational Research: Clinical evaluation of novel treatments, assessment of efficacy and safety, and translation of basic research into clinical applications.
- Cell and Gene Therapy: Cellular therapies including CAR T-cell therapy, immune cell functional assessment and development of new therapeutic modalities.
- Supportive Care, Palliative Care and Patient Support: Management of treatment-related adverse events, quality of life (QOL), cancer survivorship and multidisciplinary collaboration.
Pharma Nexus highlights: Relevant research technologies include spatial proteomics, multiplex immunofluorescence, digital pathology, flow cytometry, organoids, single-cell analysis, cell culture and drug discovery screening. Research on the tumor microenvironment using patient-derived specimens and discovery of biomarkers associated with therapeutic response or drug resistance are particularly relevant to the interface between basic and clinical research. These are related technologies identified by Pharma Nexus, not confirmed presentations, exhibited products or validated clinical diagnostic applications at the 65th annual meeting.
Official information: Japan Society of Clinical Oncology: Scientific and Clinical Resources
Call for Abstracts and Research Presentations
The preliminary planning document for the 65th annual meeting anticipates approximately 1,800 abstract submissions. This is an estimate based on previous meetings, not a confirmed number of accepted abstracts or presentations.
- Abstract Submission Opening Date and Deadline: Under preparation.
- Eligibility, Abstract Categories and Formatting Requirements: Under preparation.
- Oral and Poster Presentations and Presentation Languages: Details not confirmed.
- Acceptance Notifications and Presenter Registration Requirements: Under preparation.
Prospective presenters should consult the official submission guidelines and JSCO requirements concerning research ethics and conflicts of interest (COI). Submission dates and requirements from the 64th annual meeting in 2026 have not been applied.
Official information: Future Annual Meeting and Abstract Submission Updates
Scientific Program and Expected Meeting Scale
The society’s preliminary planning document dated June 17, 2025, provides the following estimates. These figures are based on previous meeting arrangements and do not constitute the confirmed 2027 program.
| Item | Planning Estimate |
|---|---|
| Participants | Approximately 8,000 |
| Abstract Submissions | Approximately 1,800 |
| International Invitees | Approximately 30 |
| Associated Educational Seminars | 3 |
| Academic Seminar Slots | 69 |
| Evening Seminar Slots | 3 |
| Sponsored Symposium Slots | 9 |
| Patient Advocate Leadership (PAL) Slots | 2 |
| Corporate Exhibitors | 45 companies |
| Public Lectures | 2 (approximately 500 participants each) |
The associated seminars envisioned in the planning document include an education seminar, a seminar for medical staff and a communication skills seminar for certified cancer care network navigators. Two public lectures are envisioned, one near the president’s institution and one during the annual meeting. Detailed lecture topics, speakers, timetables and venue assignments remain under preparation.
Official information: 65th Annual Meeting Preliminary Planning Document (Japanese)
Registration and Fees
Registration dates, participation fees and registration categories for the 65th Annual Meeting of the Japan Society of Clinical Oncology remain under preparation.
- Advance and On-Site Registration: Under preparation.
- Registration Fees, Membership Categories and Student Rates: Under preparation.
- Specialist Certification Credits and Educational Seminar Requirements: Details not confirmed.
- Online Viewing and On-Demand Streaming: Details not confirmed.
- Patient and Advocate Programs and Accommodation: Details not confirmed.
Meeting registration and abstract submission may require separate procedures. Please consult the official guidelines. Registration fees and streaming arrangements from the previous annual meeting have not been applied to the 2027 meeting.
Official information: 65th Annual Meeting and Registration Updates
Corporate Sponsorship and Exhibition Opportunities
The preliminary planning document anticipates 45 corporate exhibitors, 69 academic seminar slots, three evening seminar slots and nine sponsored symposium slots. Official sponsorship guidelines, exhibition fees, application deadlines, exhibition dates and booth specifications for 2027 remain under preparation.
- Corporate Exhibitions and Industry Information Exchange: 45 companies anticipated in the planning document. Official exhibitor requirements not confirmed.
- Sponsored Seminars and Symposia: Preliminary slot estimates published; application requirements under preparation.
- Sponsorship Application Deadlines and Fees: Under preparation.
- Booth Specifications and Move-in/Move-out Schedules: Details not confirmed.
Relevant Industries: Anticancer drugs, therapeutic antibodies, molecular diagnostics, genetic analysis, immunostaining reagents, research imaging systems, cell culture, drug discovery services, medical devices and clinical research support services.
The 2025 call for meeting management contractors concerns the selection of a company to manage the annual meeting. It is not an exhibitor application announcement for the 2027 event. Prospective exhibitors should consult the forthcoming official sponsorship prospectus and eligibility requirements. Sponsorship conditions from the 64th annual meeting have not been treated as confirmed conditions for 2027.
Official information: Preliminary Planning Document and Expected Exhibition Scale (Japanese) / JSCO Latest Announcements
Venue and Access
Fukuoka Convention Center
Fukuoka Convention Center comprises multiple convention facilities in the waterfront district of Hakata-ku, Fukuoka. The official JSCO announcement identifies Fukuoka Convention Center as the venue for the 65th annual meeting, but the specific facilities and halls to be used have not been confirmed.
Reference: Facilities in the Convention District
- Fukuoka International Congress Center: 2-1 Sekijomachi, Hakata-ku, Fukuoka, Japan.
- Marine Messe Fukuoka Hall A: 7-1 Okihamamachi, Hakata-ku, Fukuoka, Japan.
These facilities are listed for reference and have not been confirmed individually as venues for the 65th annual meeting. Nishitetsu buses connect the convention district with Hakata Station and Tenjin. Please consult forthcoming official announcements for registration locations, scientific session venues, corporate exhibition areas and transportation arrangements.
Official information: Fukuoka Convention Center Official Website / Fukuoka International Congress Center Facility and Access Guide
Official Websites
65th Annual Meeting of the Japan Society of Clinical Oncology (English)
JSCO Upcoming Annual Meetings (Japanese)
Meeting Overview, Preliminary Plan and Expected Scale (Japanese)
Japan Society of Clinical Oncology Official Website
Kobe University Division of Urology
Information checked November 13, 2026. The meeting dates, venue, president and theme are based on official announcements by the Japan Society of Clinical Oncology. Attendance, abstract submissions, corporate exhibitor numbers and seminar slots are preliminary estimates from the planning document dated June 17, 2025, not confirmed figures. Please consult forthcoming official announcements for abstract submissions, registration, the detailed scientific program and sponsorship requirements.
